PDS Biotechnology

19 March 2019 NetScientific plc (“NetScientific” or the “Company”) PDS merger with Edge Therapeutics update Further to its announcements on 26 November 2018 and 18 March 2019, the Company announces that its ownership of the enlarged PDS Biotechnology Corporation (“PDS”), trading on Nasdaq under the ticker PDSB, on a fully-diluted basis is 8.15%, which at the listing price on 18 March 2019 of …

Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer Growing product pipeline utilising Versamune®, a novel, versatile, multi-functional platform Phase 1/2 clinical data on lead product candidate PDS0101 suggests immunotherapeutic anti-cancer activity and favourable safety profile in early stage cervical cancer Combined company plans to initiate multiple Phase 2b/3 clinical trials of PDS0101 in HPV-associated cancers …

London, UK – July 10th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, announces a new clinical trial collaboration agreement between its portfolio company PDS Biotechnology Corporation (“PDS”) and a subsidiary of Merck & Co., Inc. (known as MSD outside the United States and Canada). The agreement will enable PDS to evaluate the combination of its Versamune®-based PDS0101 …

RNS Number : 0007V NetScientific PLC 13 April 2016 NetScientific plc (“NetScientific” or the “Company” or the “Group”)   NetScientific Portfolio Company PDS Biotechnology will embark on multiple Phase 2 studies following positive results following the completion of its Phase I study for PDS0101 Immunotherapy for HPV-Related Cancers   London, UK – 13/4/2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is pleased …